Abstract
INTRODUCTION
Congenital diaphragmatic hernia (CDH) is a complex and potentially fatal developmental defect. The incidence is approximately 1 in 5000 births, and it is associated with a mortality rate ranging from 8 to almost 80% [1] . It results from a defect in the developing diaphragm that allows the herniation of abdominal viscera into the thorax. This not only causes physical compression of the lungs but also impedes the normal development of the terminal bronchioles, alveoli and pulmonary vessels bilaterally, despite the defect often being unilateral [2] . Pulmonary hypoplasia and persistent pulmonary hypertension due to thickening of the pulmonary vasculature can occur as a result of this process producing respiratory failure within the newborn [3] .
The management of CDH can be divided into antenatal and postnatal. The standard of care in the antenatal period involves expectant management with surveillance for complications, although a recent meta-analysis by Al-Maary et al. suggests that foetal tracheal occlusion may be beneficial in neonates with CDH and severe pulmonary hypoplasia [4] . The postnatal approach focuses on supportive management followed by surgical repair. Supportive therapy can involve inhaled nitric oxide, highfrequency oscillatory ventilation (HFOV) and extracorporeal membrane oxygenation (ECMO).
The first reported use of ECMO for infants with CDH was in 1977; although there have been great advances in the technology, the fundamental principles have remained the same [5] .
Surgical repair of the diaphragmatic defect was traditionally undertaken once cardiovascular stability has been achieved using various approaches, although there is controversy in the literature with regard to optimal timing of repair. In our centre, we favour an early repair on ECMO when possible. Despite advances in conservative and surgical intervention, the mortality and morbidity rates associated with CDH remain significantly high. There are no universally accepted criteria for the initiation of ECMO in neonates with CDH or timing of repair once commenced on ECMO.
We share our 26-year experience of ECMO in patients with CDH in a tertiary referral centre, trying to identify factors affecting survival outcome for repair of CDH with ECMO as a bridge to surgery and/or recovery.
METHODS
We retrospectively analysed data from Extracorporeal Life Support Organization registry forms between 1989 and 2015 (26-year period) and collected data regarding date of admission, Apgar scores, gestational age, mode of delivery, birth weight, side of defect, other comorbidities, pre-ECMO arterial blood gas, ventilation strategy, timing of repair, mode of ECMO, haemorrhagic, neurological, renal and pulmonary complications and survival to discharge from the ECMO Unit. Overall long-term survival data were obtained from the National Health Service SPINE system.
In our centre, there are no defined criteria for the initiation of ECMO in patients with CDH, and each case is judged individually by our specialist ECMO team in conjunction with our neonatal intensivists and congenital cardiothoracic surgeons. In general, most neonates with CDH who have severe respiratory failure despite an optimal ventilator strategy and/or severe haemodynamic compromise in the absence of a severe comorbidity will be considered for ECMO in our centre. Contraindications for ECMO are significant intracranial bleeding (Grade 2 and above) and any other contraindications to limited heparinization as well as contraindications to continuation of active treatment, e.g. patients in whom a major chromosomal abnormality is suspected.
Once neonates were stabilized on ECMO, we would aim to perform the CDH repair on ECMO at the earliest opportunity when possible. All repairs were performed either by the specialist ECMO consultant or by one of our congenital cardiothoracic surgeons.
Statistical analysis
All data were analysed using SPSS windows (IBM SPSS Statistics 20, Armonk, NY, USA). Survival analyses were estimated using the Kaplan-Meier method, with log-rank test to compare for differences between the groups. An event was defined as death due to any cause. Patients with no event were censored at the time of last known to be alive. The multivariable model was created using a Cox regression analysis. Variables with a P-value <0.1 in the univariable analysis were included in the multivariable analysis. All variables were kept in the multivariable model without further model selection.
RESULTS
Between 1989 and 2015, 98 neonates with CDH requiring ECMO were identified. Fifty-nine were male (60.1%) with a mean gestational age of 38.4 weeks (SD ±1.7 weeks; range 33-42). Fifty-six (57.1%) neonates were delivered via normal vaginal delivery, with the remainder via caesarean section. Eighty-six neonates (87.8%) had a left-sided defect. There were no neonates with a bilateral defect. Seven neonates (7.1%) had an associated cardiac pathology. Of these, 2 had pulmonary hypoplasia, 2 had a ventricular septal defect, 1 had hypertrophic cardiomyopathy, 1 had aortic arch hypoplasia and 1 had an interrupted aortic arch with truncus arteriosus and a single coronary artery.
A summary of parameters including birth weight, Apgar scores and pre-ECMO arterial blood gases are summarized in Table 1 .
Thirty neonates (30.6%) were started with HFOV prior to the initiation of ECMO. We would aim to start all neonates on inhaled nitric oxide prior to ECMO. Forty-nine neonates (50%) were initiated with inhaled nitric oxide by the referring hospital. Ninety-four neonates (95.9%) required a vasopressor and/or inotropic support prior to ECMO.
The vast majority of neonates (95.9%) were initiated with ECMO primarily for pulmonary support. Fifty-eight neonates (59.2%) were initiated with veno-arterial (VA) ECMO. Thirty-nine neonates (39.8%) were on veno-venous (VV) ECMO. One neonate required extracorporeal cardiopulmonary resuscitation following a cardiac arrest. ECMO support was later withdrawn and the neonate did not survive.
Our in-hospital survival was 68%, and our overall survival over a 26-year period was 52.1%. Our 1-year survival was also 52.1% (Fig. 1) . Eighty-two neonates (83.7%) had the defect repaired on ECMO while 13 (13.3%) underwent repair prior to ECMO and 3 (3%) underwent repair following ECMO. There was no statistically significant difference in survival in the timing of the repair on univariable analysis (P = 0.653; Fig. 2 ). Analysis of prognostic factors on overall survival are summarized in Table 2 .
Since the introduction of mobile ECMO in our unit in 2010, 16 of the 32 neonates in this group (50%) were transferred to our centre using mobile ECMO. Mobile ECMO was not an independent factor associated with a significant difference in survival (P = 0.675).
The presence of any neurological complication was associated with a reduction in survival (Fig. 3) , as were the neonates who required continuous renal replacement therapy (Fig. 4) .
We also compared cumulative survival in the last 10 years 
DISCUSSION
This is one of the largest single-centre cohort of patients in a tertiary centre, where defects are primarily repaired on ECMO. The effect of ECMO on survival rates in neonates with CDH has been established, although there are several controversies that remain. This is partly because of the variability in indications for ECMO between individual centres due to the lack of standardized guidelines as well as lack of consensus on prognostic factors for the initiation of ECMO in neonates with CDH. This was mainly due to lack of evidence with the majority of studies containing small patient numbers from single-centre studies. In an attempt to address this issue, the congenital diaphragmatic hernia group developed a large multicentre study that included 632 neonates and found that ECMO significantly improved survival in those with a mortality risk above 80% [6] .
In another attempt to overcome the limitation of small study size, Morini et al. [1] completed a systematic review of 21 nonrandomized studies comparing mortality in a pre-ECMO era to an era when ECMO was available. They reported a significant improvement in early and late mortality in patients deemed ECMO candidates during the period when ECMO was available; however, improvements in other aspects of CDH management may be accountable for this result. This is corroborated by D'Agostino et al. [7] who report an increase of 32% in the survival rate at their centre after the introduction of ECMO. Morini et al. also undertook a meta-analysis that included the randomizedcontrolled trials comparing ECMO to conventional ventilation and found improved in-hospital survival with ECMO but no difference in later out-of-hospital survival [1] .
Our in-hospital survival rate of 68% is consistent with the survival in the literature. The international ECMO registry reported survival at 52% [8] . It is also worth noting that most studies assessing survival refer to survival to discharge. While Davis et al. [9] report a 58% survival rate at discharge for CDH patients who received ECMO, this dropped to 37% at 1 year. In our study, our 1-year mortality is 52.1%. During our follow-up period of 26 years, our overall survival was 52.1%. We are currently unable to calculate median for overall survival, as our data have not fully matured because more than half of our cohort are still alive and we have included recent patients who do not have long-term follow-up data. Interestingly enough, all mortalities occurred within the first 7 months from ECMO unit discharge. Beyond this, there was no further mortality in this cohort. This could suggest that if these neonates survive the initial insult, they may go on to have a sustained survival benefit. However, we did not have long-term morbidity data available, and it has been established that there is significant morbidity in this cohort compared to the rest of the respiratory neonatal ECMO population who survive [9] . As a tertiary centre, we receive referrals from all over the country for ECMO and therefore appreciate that the patients in our cohort are a selected group, as they made it as far as receiving ECMO. There is therefore a population of patients who either were not offered treatment or died before referral to our centre who are not accounted for in this study.
There is some controversy regarding optimal timing of repair and ECMO. In our centre, we favour repair on ECMO (83.7%). Twenty-two patients were recorded as having some postoperative bleeding, requiring manipulation of heparin management, administration of clotting factors, administration of antifibrinolytics (aprotonin being the drug of choice in our centre) and/or surgical re-exploration. In our study, the vast majority of these 22 patients who bled (90%) were repaired on ECMO. However, bleeding itself was not associated with any significant difference in survival. It is not surprising that the majority of bleeding occurred in this population as the majority of our cohort were repaired on ECMO. We compared bleeding rates between those repaired on ECMO (24%) and off ECMO (11.8%) and found no statistically significant difference on independent sample t-test (P = 0.25). The timing of repair was not associated with any survival difference in our study, although a recent study by Kays et al. suggests improved survival with earlier repair on ECMO [10] .
There have been many single-centre studies that have demonstrated improved survival with HFOV, possibly due to the ability to achieve higher mean airway pressures without the associated barotrauma [11] [12] [13] [14] [15] [16] . However, in a recent randomized control trial by Snoek et al. [17] , there was no difference in survival between conventional ventilation and HFOV in neonates with prenatally diagnosed CDH. They also found that neonates with conventional ventilation had a shorter duration of ventilator and inotopic support and were less likely to be placed on ECMO.
The use of HFOV has become the preferred method of ventilation in recent years, with all neonates receiving HFOV in our study from 2013. In our series, HFOV appeared to be beneficial on univariable analysis, although this was no longer statistically significant on multivariable analysis. This is consistent with some of the findings in the literature and supports the fact that attributing improving survival primarily to HFOV is misleading and may be due to an era bias.
Our survival after 2005 was significantly better than survival prior to 2005. We have decided to use this date as a cut-off, as we feel there have been a number of changes to our practice including switching from a roller pump to a centrifugal pump system, shorter circuit lengths and the introduction of a dedicated mobile ECMO service in our unit as well as overall improvements in neonatal intensive care.
The improvements in survival rates attributed to ECMO have been challenged by several studies. Tam et al. [3] analysed the survival rate of neonates with CDH for whom ECMO was indicated in a Hong Kong centre with no access to ECMO. They found a similar survival rate of 67%; however, this was based on only 6 subjects who required ECMO. The survival rate for neonates requiring ECMO as reported by the international ECMO registry is 52% [8] . Furthermore, 2 similar studies report similar survival rates, despite ECMO being used in 50% of neonates in one study and 1% in the other, lending evidence to the idea that other interventions may be responsible for improving survival rates [18, 19] . We believe that improved survival rates may be linked to a combination of improvement in neonatal critical and intensive care, advancement in ECMO circuit technology and the use of a specialist ECMO team. Although mobile ECMO was not an independent variable affecting survival in our cohort, we believe the introduction of a specialist mobile ECMO service in our unit in 2010 may also have contributed to improved survival. Mobile ECMO allows for earlier initiation of ECMO support and provides an option for neonates who may not have otherwise survived conventional transfer. Our experience over time has increased, allowing us to constantly look at ways to improve patient outcomes and has enabled us to evolve our practice. We feel the delivery of ECMO is best suited to centres in which a specialist multidisciplinary team approach can be utilized. In keeping with other studies into survival in ECMO patients, the use of continuous renal replacement therapy and neurological complications remain predictors of poor outcome, even in the sicker CDH population [20, 21] . The use of continuous renal replacement therapy in ECMO patients as well as paediatric intensive care unit patients in general has been recognized as a predictor of poor outcome [21] . It has also been well established that significant neurological events during ECMO not only are associated with increased mortality but also have increase in neuro-developmental delay and negatively impact on quality of life [20] . The primary measure of outcome in this study was survival. However, our study did not assess long-term comorbidities and quality of life. It is known that there are high rates of both physical and neuro-developmental disabilities in this cohort [9] . This is an area for further research in addition to assessing the long-term economic viability to truly understand the outcomes of ECMO on CDH.
CONCLUSIONS
Based on our own experience and data within the literature, we believe that all neonates with severe CDH should be assessed on a case-by-case basis and given the option of ECMO if clinically indicated. There is not enough evidence both in the literature and in our cohort to identify definitive predictors of survival in this group. From our experience, early repair on ECMO is a safe option, and provided they survive the initial postoperative insult, these patients may go on to have a sustained survival benefit.
Further research into the long-term impact on quality of life and cost-effectiveness needs to be undertaken to assess the true outcomes of ECMO in neonates with severe CDH.
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